Ethnicity and Equity: Missing the Point

To the Editor:

We read with interest the recent editorial by Fustinoni and Biller on ethnicity and stroke.1 We feel that ethnicity is a critical aspect of understanding stroke outcomes, particularly within the Pacific rim, and are concerned by what appears a dismissive and cursory approach to the subject.

Despite the variation in definitions of “ethnicity” and “stroke,” ethnicity has consistently been shown to be a significant variable for stroke. Ethnic differences in stroke incidence and stroke-related mortality have been well documented in the United States, Europe, and New Zealand.2–4 Differences in risk factor prevalence and management,5,6 utilization of services,7 and functional and motor impairments8 have also been described to a lesser extent.

We agree with the suggestion of Fustinoni and Biller that lower socioeconomic status and associated risk factors may explain some of the stroke burden carried by ethnic minority populations. However, within each social class, premature stroke mortality still remains substantially greater for black men than white men in the United States9 and for Maori than non-Maori in New Zealand.10

Despite the increased stroke incidence rates, increased stroke severity and poor functional outcomes, mortality rates, and discharge destinations are the same for both black and white populations in Europe,1 and our recent work found that such outcomes are better for non-Europeans than Europeans in New Zealand. This challenges the fallacy that ethnic minorities are an unhealthy burden and that “whites” are the “gold standard.” We propose that the family unit plays a pivotal part in this important stroke outcome and that more attention should be directed toward supporting their role in stroke care.

Finally, we believe that as an editorial on ethnicity and stroke, the article by Fustinoni and Biller missed the main point. Although genetic research may explain some of the differences reported, current literature suggests that equity of stroke care does not exist for ethnic minorities. Accessibility, quality of service, and equity cannot be separated when delivering effective stroke care. There is little information about access to and the quality of stroke care services for any ethnic minority group. Perhaps rather than attempting to locate a responsible gene(s), such a refocus of research demands more attention in order to guide practical action. Some may find ethnicity and stroke research repetituous, but it is a fundamental tool for assessing need and monitoring the impact of health policy.

A sense of control over one’s health and a sense of hope are important determinants of health status.11 We believe that these are best achieved when there is partnership between researchers, health providers from ethnic minority groups, and the communities themselves on ethnic-specific research. In doing so we aim to encourage participation of all ethnic groups in stroke research and identify barriers to stroke care. Obtaining this information is just one step in the development of a framework to improve stroke outcomes. The humanitarian and economic rewards for reducing ethnic disparities are great,12 but further quality research is needed for these rewards to materialize.

Kathryn McPherson, PhD
Rehabilitation Teaching and Research Unit
Wellington School of Medicine
Wellington South, New Zealand


Response

We thank Drs Harwood, McNaughton, McPherson, and Weatherall for their interest in our editorial.1 We agree that there may well be patterns of disease that distinguish different ethnic groups. We do not agree that these differences may be determined “despite the variation in definitions of ethnicity.” If groups that are to be matched are not properly defined on the basis of comparable features, results will be flawed. If various but incorrect criteria are applied repeatedly, results may appear “consistent” but in fact only reflect a marred methodology. All the more so with a variable that is defined socially rather than scientifically. For instance, one of the studies cited by Harwood compares stroke incidence between white, black (defined by skin color) and Hispanic (defined by language) residents of an urban community in Manhattan.2 Another reports stroke incidence among Maori, Pacific Islands people (defined by place of birth), and “Europeans” in Auckland.3 Not surprisingly, Europeans is not defined as a group, it is just included. Of course, how does one classify a European? By birth, descent, language, or merely “appearance”? One strongly suspects that “Europeans” in Auckland would probably be “whites” in the United States. Moreover, “persons of Indian or Chinese origin were included with Europeans because there were too few.”4 Can results obtained in this way be consistent? Harwood and colleagues point out that even if purportedly “ethnic” differences may be explained by socio-
economic factors, within each social class premature stroke mortality remains greater for blacks and Maoris than for whites and non-Maoris. This could perhaps reflect a real ethnic difference. It could also be the result of a different social and therapeutic attitude in the management of stroke toward blacks and Maoris. It is curious that in many published reports, ethnic minorities have usually fared worse, notwithstanding the fact that in some instances mortality, discharge destinations, and outcome have been similar or even better in minorities. In any case, results will continue to be controversial if ethnic groups are not properly defined and other possible variables not looked at.

We cannot fully agree that accessibility, quality of service, and equity cannot be separated when delivering stroke care and that information in this respect is scarce regarding minorities. Nevertheless, as we showed, genetic research has provided some breakthroughs that have not entirely been expected, in some cases disproving false “ethnic” assumptions. This was the main point of our editorial.

O. Fustinoni, MD
Department of Neurology
University of Buenos Aires
Buenos Aires, Argentina

J. Biller, MD
Department of Neurology
Indiana University School of Medicine
Indianapolis, Indiana

To the Editor:

The Abciximab in Ischemic Stroke Investigators reported the encouraging results of their randomized, double-blind, placebo-controlled, dose-escalation trial. Of 74 eligible and consenting patients presenting within 24 hours of onset of their ischemic stroke, 54 patients were treated with 4 escalating doses of intravenous abciximab and 20 patients with placebo. The scheduled post-study CT brain scan detected asymptomatic parenchymal hemorrhages in 7% of abciximab-treated patients and 5% of placebo-treated patients; another 11% of abciximab-treated patients had asymptomatic parenchymal hemorrhages on unscheduled brain imaging (CT or MRI) performed on days 2 through 35. Symptomatic hemorrhagic transformation was not seen, while asymptomatic parenchymal hemorrhages were associated with a higher baseline National Institute of Health Stroke Scale (NIHSS) score. We would raise the following issue for clarification by the authors and report our limited experience of using abciximab in Chinese patients.

Concomitant use of antithrombotic medications during the time period of diagnosing parenchymal hemorrhage was listed in Table 3 of the article. The scheduled CT brain scan detected asymptomatic parenchymal hemorrhages in patients A, D, G, H, and I, who also received concomitant antithrombotic medications, such as systemic heparin, low-dose heparin, aspirin, and warfarin sodium. Nevertheless, the study protocol required that antplatelet agents or anticoagulants not be administered until the results of the scheduled CT brain scan became available (as stated in the subsection on Ancillary Care within Subjects and Methods). The investigators stated that they were not certain whether these agents were administered before or at the time of hemorrhage. While it is conceivable that some patients might be taking regular aspirin at the time of admission, the administration of systemic, low-dose, and low-molecular-weight heparin could only be in-hospital, and so their commencement time should be well documented in the study.

With a background similar to that indicated in the article by the Abciximab in Ischemic Stroke Investigators, we designed a pilot study to evaluate the safety issue of administering intravenous abciximab in Chinese patients within 6 hours of symptom onset. Our regimen was a 0.22-mg/kg intravenous bolus of abciximab followed by intravenous infusion at 9 μg/min for 12 hours. Concomitant use of oral antiplatelet agents was permitted. Of 2 consenting patients who received intravenous abciximab, the second patient had a fatal hemorrhagic transformation of his acute cerebral infarction.

This patient was a 65-year-old man with a history of hypertension, ischemic heart disease, peripheral vascular disease, hypercholesterolemia, mild bilateral carotid artery stenosis, and right vertebral artery occlusion. He had 2 previous episodes of nondisabling ischemic stroke and was taking aspirin and ticlopidine. He was admitted for percutaneous angioplasty to his stenotic left subclavian artery. On the morning of the day of the scheduled angioplasty, he developed right-sided weakness, with an NIHSS score of 8 and a Glasgow Coma Scale (GCS) score of 15. The clinical diagnosis was a recurrent lacunar infarction. The initial CT brain scan revealed old infarcts over the left middle cerebral artery territory, with no interval change when compared with the last CT brain scan performed 6 months before. Informed consent was obtained from the patient and his relatives, and intravenous abciximab was commenced at 5 hours after symptom onset. He was allowed to continue his oral medications, including enteric-coated aspirin (at 100 mg QD) and ticlopidine (which was reduced from 250 mg BID to 250 mg QD). Reassessment at 10 hours after onset showed an NIHSS of 6, but his relatives noted dramatic recovery at 14 hours after onset. Nevertheless, he deteriorated at 10 hours after commencement of intravenous infusion of abciximab (ie, at 15 hours after onset). He had dense right hemiplegia; his GCS score was 9. Repeat CT brain scan

CT brain scan showing massive left-sided hemorrhagic transformation of both the acute and old cerebral infarcts, with marked mass effect and intraventricular bleeding.


Fatal Hemorrhagic Transformation of Acute Cerebral Infarction After the Use of Abciximab

To the Editor:

The Abciximab in Ischemic Stroke Investigators reported the encouraging results of their randomized, double-blind, placebo-controlled, dose-escalation trial. Of 74 eligible and consenting patients presenting within 24 hours of onset of their ischemic stroke, 54 patients were treated with 4 escalating doses of intravenous abciximab and 20 patients with placebo. The scheduled post-study CT brain scan detected asymptomatic parenchymal hemorrhages in 7% of abciximab-treated patients and 5% of placebo-treated patients; another 11% of abciximab-treated patients had asymptomatic parenchymal hemorrhages on unscheduled brain imaging (CT or MRI) performed on days 2 through 35. Symptomatic hemorrhagic transformation was not seen, while asymptomatic parenchymal hemorrhages were associated with a higher baseline National Institute of Health Stroke Scale (NIHSS) score. We would raise the following issue for clarification by the authors and report our limited experience of using abciximab in Chinese patients.

Concomitant use of antithrombotic medications during the time period of diagnosing parenchymal hemorrhage was listed in Table 3 of the article. The scheduled CT brain scan detected asymptomatic parenchymal hemorrhages in patients A, D, G, H, and I, who also received concomitant antithrombotic medications, such as systemic heparin, low-dose heparin, aspirin, and warfarin sodium. Nevertheless, the study protocol required that antplatelet agents or anticoagulants not be administered until the results of the scheduled CT brain scan became available (as stated in the subsection on Ancillary Care within Subjects and Methods). The investigators stated that they were not certain whether these agents were administered before or at the time of hemorrhage. While it is conceivable that some patients might be taking regular aspirin at the time of admission, the administration of systemic, low-dose, and low-molecular-weight heparin could only be in-hospital, and so their commencement time should be well documented in the study.

With a background similar to that indicated in the article by the Abciximab in Ischemic Stroke Investigators, we designed a pilot study to evaluate the safety issue of administering intravenous abciximab in Chinese patients within 6 hours of symptom onset. Our regimen was a 0.22-mg/kg intravenous bolus of abciximab followed by intravenous infusion at 9 μg/min for 12 hours. Concomitant use of oral antiplatelet agents was permitted. Of 2 consenting patients who received intravenous abciximab, the second patient had a fatal hemorrhagic transformation of his acute cerebral infarction.

This patient was a 65-year-old man with a history of hypertension, ischemic heart disease, peripheral vascular disease, hypercholesterolemia, mild bilateral carotid artery stenosis, and right vertebral artery occlusion. He had 2 previous episodes of nondisabling ischemic stroke and was taking aspirin and ticlopidine. He was admitted for percutaneous angioplasty to his stenotic left subclavian artery. On the morning of the day of the scheduled angioplasty, he developed right-sided weakness, with an NIHSS score of 8 and a Glasgow Coma Scale (GCS) score of 15. The clinical diagnosis was a recurrent lacunar infarction. The initial CT brain scan revealed old infarcts over the left middle cerebral artery territory, with no interval change when compared with the last CT brain scan performed 6 months before. Informed consent was obtained from the patient and his relatives, and intravenous abciximab was commenced at 5 hours after symptom onset. He was allowed to continue his oral medications, including enteric-coated aspirin (at 100 mg QD) and ticlopidine (which was reduced from 250 mg BID to 250 mg QD). Reassessment at 10 hours after onset showed an NIHSS of 6, but his relatives noted dramatic recovery at 14 hours after onset. Nevertheless, he deteriorated at 10 hours after commencement of intravenous infusion of abciximab (ie, at 15 hours after onset). He had dense right hemiplegia; his GCS score was 9. Repeat CT brain scan
revealed massive hemorrhagic transformation involving both the presumed site of acute cerebral infarction and the old cerebral infarcts (Figure). Transfusion of platelet concentrates was given, and the neurosurgeon recommended conservative treatment. He became comatose and died 12 hours after onset of the sudden deterioration (ie, at 27 hours after onset, or at 22 hours after intravenous abciximab). Further recruitment of stroke patients into this safety study was stopped. After reading the encouraging results from the Abciximab in Ischemic Stroke Investigators, we will seek the approval of our Ethics Committee to modify our protocol and continue our safety study in Chinese patients with acute ischemic stroke. We will use a lower dose of intravenous abciximab for the 12-hour infusion and will avoid concomitant use of other antithrombotic medications such as aspirin.

**Abciximab (ReoPro) was kindly provided by Eli Lilly Asia Inc.**

 Raymond T.F. Cheung, MBBS, PhD, FRCPE  
Division of Neurology  
Queen Mary Hospital  
Hong Kong  
  
David S.W. Ho, MBBS, PhD, FRACP  
Division of Cardiology  
Department of Medicine  
Queen Mary Hospital  
Hong Kong

**Response**

I thank Drs Cheung and Ho for their letter and for the opportunity to clarify the information included in Table 3 of the dose escalation study of abciximab.1 Our data collection forms listed all ancillary agents given during the first 5 days after enrollment, and that information is included in Table 3. Obviously, this material spans the time of the mandated CT examination, performed at approximately 24 to 36 hours after entry. As Drs Cheung and Ho noted, the protocol stated that antiplatelet agents and anticoagulants could not be started until after the completion of the CT study. To ensure the accuracy of the information, we contacted the sites that enrolled the 5 patients in question (A, D, G, H, and I) to reconfirm that treatment with an anticoagulant or antiplatelet agent was not started before the scan was obtained. The sites report that no stroke-preventive medications had been started in these 5 cases before the CT was performed.

Abciximab is a potent antiplatelet agent, and some cases of symptomatic hemorrhagic transformation are possible. The report by Drs Cheung and Ho of a case of fatal intracranial hemorrhage following administration of abciximab is sobering. They point out that their patient had received ticlopidine and aspirin, which might have contributed to a higher risk for symptomatic hemorrhage. While the study made every effort to avoid situations that might have been associated with a high bleeding risk, the dose escalation study was primarily focusing on safety, we wanted to avoid any concomitant medications that might cause bleeding. The experience of Drs Cheung and Ho emphasizes the importance of determining the potential risks before testing the efficacy of any new therapy for stroke. Their experience also should prompt care about giving other medications that affect coagulation simultaneously with abciximab to patients with acute ischemic stroke.


**Chlamydia pneumoniae Infection and PFO-Associated Ischemic Stroke**

**To the Editor:**

Ischemic stroke in young adults is a topic that has received increasing attention in recent years and has been accompanied by descriptions of case series in which the relative frequencies of risk factors and presumed etiology are assessed.1 A number of epidemiological and pathogenic studies have been published on the association between *Chlamydia pneumoniae* infection and ischemic stroke. The results are, however, controversial. These studies show a high degree of heterogeneity in the selection of patients and controls and in the interpretation of serological results.2-3 Wimmer et al4 studied a series of stroke patients aged <50 years. They concluded that chronic *C pneumoniae* infection is associated with an increased risk of stroke and TIA but were unable to detect any correlation between antibody titers and etiologic stroke subtypes.

Our study was designed to evaluate the potential role of *C pneumoniae* infection in specific etiologic subtypes of stroke in young patients. In our consecutive series of 101 patients with ischemic stroke, aged <46 completed years, and 101 matched controls, we evaluated *C pneumoniae* IgG and IgM antibodies by means of the microimmunofluorescence method. When the study was planned, the detection of IgA was not yet available. There was a statistically significant difference between the 2 groups with regard to the frequency of active chronic *C pneumoniae* infection (IgG ≥1:512) (25.7% versus 7.8%, *P*<0.05). After adjustment for cerebrovascular risk factors, the OR for inactive chronic infection (IgG ≤1:256) was 1.3 (95% CI 0.6 to 3.2), whereas that for active chronic infection was 2.7 (95% CI 1.0 to 7.3).

Furthermore, we considered serological patterns for the following etiologic subtypes: (1) atherosclerosis, (2) cardioembolism (80% of patients had a "high-risk" patent foramen ovale [PFO; eg, width >2 mm] and larger amounts of intratral shunting, or PFO in association with atrial septal aneurysm),5 (3) nonatherosclerotic vasculopathy (arterial dissection, arteritis), (4) procoagulant conditions, and (5) undetermined cause. Although we did not find any significant difference between stroke etiologic subtypes, a positive trend toward an increased prevalence of active chronic *C pneumoniae* infection was found in the cohort of 35 patients with PFO (13 of 35, 7 of these 13 had IgG titers equal to 1:1024). In the remaining 66 stroke patients, only 5 had the higher IgG titers. Considering these data, what pathogenetic mechanisms might link active chronic *C pneumoniae* infection and PFO as a cause of stroke? Might *C pneumoniae* reinfection induce a transient procoagulant state and be an additional risk factor for symptomatic emboli, when a potential route for paradoxical emboli is patent? Because the lungs are the usual site of *C pneumoniae* infection, is the spreading of the pathogen from the lungs to the endothelium of the heart pathogenically plausible from an anatomic and physiopathological point of view?

Our preliminary study has certain limitations, such as the relatively small sample size, if compared with the 5 etiologic categories we considered, which may have limited the power of the statistical analysis performed to detect possible correlations. These correlations would require a larger study, perhaps including...
PCR and culture techniques to test whether C pneumoniae infection, besides being associated with activation of the atherosclerotic plaque at later age, might indeed explain the occurrence of ischemic events associated with PFO in the young. Nevertheless, we wish to suggest the hypothesis of a possible role of C pneumoniae infection in ischemic stroke for preventive purposes in the young, since the microorganism is susceptible to antibiotic therapy.

Maurizia Rasura, MD
Alexia Anzini, MD
Department of Neurological Sciences

M. Teresa Mascellino, MD
Department of Tropical and Infectious Diseases
University of Rome “La Sapienza”
Rome, Italy


Response

We thank Rasura et al for sharing with us their interesting data, which suggests a possible role of Chlamydia pneumoniae infection in ischemic strokes among young patients with patent foramen ovale. As the authors rightly point out, their cross-sectional study, as previous similar studies, does not prove a causative role of the agent but gives new insights into the association and raises more questions, especially into plausible mechanism(s) of association between C pneumoniae and stroke. A number of infectious agents have generated considerable research interest as possible causative agents in vascular disorders, with the greatest interest in C pneumoniae and Helicobacter pylori. Indeed, many patients with chronic coronary heart disease and carotid artery disease appear to have a chronic C pneumoniae infection, and C pneumoniae antigen has been detected in fatty streaks and atheromatous plaques. Our cross-sectional study from the West Birmingham Stroke Project also found an independent relationship between positive C pneumoniae serology and acute stroke, even after correcting for possible confounders, such as ethnic origin, age, sex, smoking habit, diabetes mellitus, steroid medication, and social deprivation. Nevertheless, it has never been entirely clear whether it is the organism itself or the virulence of the antibodies raised against it that is associated with atherosclerotic disorders. Indeed, elevated antibody titers or immune complexes containing Chlamydia lipopolysaccharide are an independent significant risk factor for acute myocardial infarction.6,7

Plausible mechanisms linking C pneumoniae and vascular disease may be an adverse influence on markers of inflammation and interaction with other vascular risk factors. For example, C pneumoniae infection is more common among smokers than nonsmokers, perhaps due to a decrease in cell-mediated immunity among smokers.8 Both acute and chronic infection with C pneumoniae are associated with an adverse lipid profile, including higher triglyceride and lower high density lipoprotein concentrations.9–11 In the West Birmingham Stroke Project, we found no apparent association between C pneumoniae antibody titers and the serum cholesterol, triglyceride, fibrinogen, and von Willebrand factor concentrations, which suggests that the prothrombotic state or endothelial dysfunction may not be the principal mechanisms of association between C pneumoniae and cerebrovascular disease.5 Indeed, each of the above vascular risk factors is independently related to atherosclerotic disease and a potential increase in the risk of stroke.

Perhaps another way to ascertain the causative link between C pneumoniae infection and vascular disease is by conducting interventional trials aiming to look at the effect of antibiotics that eradicate C pneumoniae. For example, Gupta et al12 reported that among patients after myocardial infarction, those with high titers of C pneumoniae antibodies had a significantly higher number of cardiovascular events, which was reduced with azithromycin treatment. The ROXIS study13 showed a significant reduction of the composite triple end point (cardiac ischemic death, myocardial infarction and severe recurrent ischemia) at 30 days after unstable angina-Q-wave myocardial infarction, among patients treated with roxithromycin, another macrolide antibiotic against C pneumoniae. However, 6 months after the study treatment termination, there was no longer any significant difference between the treatment and placebo groups.14 In contrast to Gupta et al,12 the ROXIS study did not find any difference in the outcome related to the baseline IgG antibody titers or to decreases in titers with antibiotic treatment. In the ACADEMIC study,15 probably the largest of the published interventional study of antibiotics in coronary artery disease, there was no significant difference in antibody titers or clinical events at the 6-month follow-up among coronary artery disease patients treated with azithromycin. We are not aware of any randomized, double-blind, placebo-controlled study of the effect of antibiotics against C pneumoniae among patients with cerebrovascular disease per se.

Thus, the question of a clinically significant relationship between C pneumoniae infection or antibodies against C pneumoniae and atherosclerotic vascular disorders, including stroke, remains largely unanswered. One cannot help but wonder whether any (possibly unknown) confounding factor has been missing in the analysis of these data.

Perhaps the story of C pneumoniae in the context of cardiovascular or cerebrovascular diseases is somewhat similar to that seen with H pylori. Indeed, there was tremendous initial enthusiasm for attempting to establish a causative link between H pylori and ischemic heart disease after initial studies demonstrated a possible association.16,17 However, this enthusiasm has suffered a setback after a few recent studies have demonstrated a lack of a significant association between H pylori and ischemic heart disease (as reviewed by Edmunds and Lip18).

Thus, in providing an answer to the question, “Is there a link between C pneumoniae and stroke?” the answer may well be a resounding “maybe.” If we were dealing with the Scottish legal system, perhaps the verdict of “not proven” (rather than the “guilty” or “not guilty” verdicts of the English legal system) would be more appropriate, which probably infers that some blame may be implied but the more serious offenders (eg, hypertension, smoking, hyperlipidemia) are more likely to be in possession of the smoking gun. Indeed, the case for a clinically significant causal relationship between C pneumoniae and atherosclerotic vascular disease (whether cerebrovascular or cardiovascular) has not yet been proved beyond reasonable doubt to justify “prosecution” with routine antibiotic therapy to eradicate C pneumoniae.

Gregory Y.H. Lip, MD, FACC
Sridhar Kamath, MRCP
Haemostasis Thrombosis and Vascular Biology Unit
University Department of Medicine
City Hospital
Birmingham, England
In reviewing the study data, we note that only 194 (12.6%) of the 1542 potential stroke subjects screened were included in the randomization. The vast majority of the stroke survivors seen in the emergency room were deemed ineligible or inappropriate for this level of care. Thus, it is difficult to generalize findings to the larger stroke population. Furthermore, the authors defined their “usual care” group as experiencing “a range of services, including... extended acute-care hospital stays; inpatient or outpatient rehabilitation; or home care via local community health clinics... ” Since only 52% in the control group received nursing visits and 50% received physical therapy visits, this implies that some patients received no rehabilitation care at all. By lumping subjects who received no or varying intensities of rehabilitation services together into one group, the potential of identifying superior outcomes for any individual level of care in this group is diluted. Therefore, it is difficult to conclude that the home care intervention is superior to any other venue of rehabilitation. A more appropriate conclusion would be that prompt discharge combined with home rehabilitation appeared to translate into a greater degree of high-level satisfaction and community integration for a select group of stroke survivors.

Another issue raised by the data are the functional levels of the groups prior to randomization. The average Barthel Scale scores of 82.7 in the “usual group” and 84.6 in the “home care group” indicate that the stroke survivors in this study had extremely mild disabilities. This compares to a mean admission Barthel score of 37 from an earlier study of 539 stroke survivors treated on 17 inpatient rehabilitation units. The mean discharge Barthel score of the inpatients was 66, which still is significantly lower than the average mean entry score of the stroke survivors in the home care protocol. Thus, the discharge planners and home care clinicians who cared for the inpatients faced even greater challenges.

Overall, the authors may not be addressing the correct question. Many studies have claimed superiority of acute rehabilitation, subacute rehabilitation, day hospital, and coordinated home care in rehabilitating stroke survivors. However, further research needs to address the optimal level of care for stroke survivors of differing functional severities. A number of authors have focused on the “middle band of stroke survivors” as the most appropriate for hospital-level rehabilitation. In contrast, stroke survivors with mild disabilities and supportive families can go directly home, and those with severe disabilities might be best served in skilled nursing or extended care facilities. Depending on the level of disability, one might triage care based on a clinical guideline, such as that proposed by the Agency for Health Care Research and Quality (formerly the Agency for Health Care Policy and Research).

With this in mind, the home care program may be a viable alternative for some patients, but it assumes that the family is capable of caring for the stroke survivor or that the stroke survivor is able to care for himself or herself. It may not be appropriate for those with complex strokes (eg, stroke survivors at risk for aspiration due to dysphagia or those who are incontinent of bowel and/or bladder, impulsive, or at risk of falling). A coordinated home care program might be more appropriate than more intensive settings for stroke survivors with mild disabilities whose goals focus more on community reintegration and instrumental rather than basic activities of daily living.

This article makes one point of importance to the rehabilitation process regardless of where it takes place. Outside of the randomization process, the authors note that the intervention empowered the subject and his or her family to take charge of decisions for rehabilitation services. If rehabilitation clinicians fail to involve stroke survivors and families in the decision-making process, and rather render them as passive observers, they are not doing their jobs.
To the Editor:

Three days before reading the article by Golledge et al.,1 I recommended carotid stenting to a 74-year-old patient with critical asymptomatic left internal carotid artery stenosis. After reading the article, I was tempted to reconsider my recommendation, but a closer analysis reveals multiple flaws in the reasoning of Golledge et al.

We have also finished our cost analysis of this study (soon to be submitted to Stroke), and our program of intervening with everyone was actually less expensive in the long run than any other option (inpatient rehabilitation in Montreal costs about $250 per day). The cost of sending even 10% of the stroke population for 4 weeks of inpatient rehabilitation in Canada would be astronomical, considering that there are 50,000 new cases of stroke in Canada per year (5000 people×30 days×$250 days = $37.5 million dollars). This would purchase a lot of home care: our intervention cost about $1000 per patient, so for the same price we could offer home support for 75% of the entire stroke population.

Although subgroup analyses are often misleading in clinical trials, the small group that went to inpatient rehabilitation did no better than those age- and severity-matched individuals who participated in the home intervention—nor did they do any worse.

Finally, we agree that empowering the patient and family to take charge is an integral part of the rehabilitation process, and that if this is not done someone is not doing his job. The experience we had with this study is that that particular rehabilitation goal is more easily operationalized and subsequently met when patients are in their own homes and not in a hospital—acute or otherwise.

By no means did this study answer all questions that about how to offer the best care, to the greatest number of patients, at the least cost. These are complex questions that would require a complex research design to answer. We hope that this project will stimulate other investigators to take up the challenge that will help patients, families, and providers in the decision-making process.

Nancy E. Mayo, PhD

for the authors

Systematic Comparison of the Early Outcome of Angioplasty and Endarterectomy for Symptomatic Carotid Artery Disease

To the Editor:

Three days before reading the article by Golledge et al.,1 I recommended carotid stenting to a 74-year-old patient with critical asymptomatic left internal carotid artery stenosis. After reading the article, I was tempted to reconsider my recommendation, but a closer analysis reveals multiple flaws in the reasoning of Golledge et al.

The authors cite 14 endovascular studies published from 1992 through 1998 involving a total of 714 carotid arteries, of which
The Time Concept in Ischemic Stroke: Misleading

To the Editor:

Wang and colleagues studied cerebral blood flow (CBF), the apparent diffusion coefficient (ADC), and brain tissue sodium concentration ([Na\(^+\)]) in the experimental animal after occlusion of the middle cerebral artery and of both common carotid arteries.\(^1\) They observed a steady increase in [Na\(^+\)] in the most severe ischemic areas with CBF \(\leq 40\) mL \(\cdot\) 100 g\(^{-1}\) \(\cdot\) min\(^{-1}\) and an ADC \(\leq 520\) \(\mu\)m\(^2\)\(\cdot\)s\(^{-1}\). They suggest the use of [Na\(^+\)] in addition to MR diffusion and perfusion imaging to exactly assess the time of stroke onset, which they regard as essential before initiating thrombolytic treatment.

The authors overlook the fact that the clinical onset of stroke in humans is not identical with the fall of CBF below thresholds that induce edema and irreversible damage. Otherwise, the reversibility of stroke symptoms would be impossible, and the penumbra concept would be invalid. The [Na\(^+\)] method may allow determination of the time point at which hyperfusion has reached a critical level in certain areas of ischemic brain tissue. This time point is presumably not identical with the time of stroke onset. The authors did not show that [Na\(^+\)] steadily increases in areas with less-severe ischemia, which may, however, be responsible for functional impairment. This reflects the obvious weakness of the time concept in ischemic stroke: the clinical symptoms may represent a volume of ischemic brain tissue with functional impairment of viable tissue, already irreversibly damaged tissue, and in most instances a mixture of both. Ischemic functional impairment can last over hours without visible brain tissue damage.\(^2\) This explains why about one third of CT scans remained normal in large stroke studies during the first 6 hours of stroke onset.\(^3,4\)

The proposed [Na\(^+\)] method, though impractical, appears to be useful in identifying the partition of ischemic tissue with developing edema after very severe ischemia. It is well established that [Na\(^+\)] highly correlates with tissue water content after arterial occlusion.\(^5,6\) There are more practical measures, however, to determine the water content of ischemic brain tissue under clinical conditions: x-ray attenuation directly correlates with the specific gravity of tissue.\(^7\) The linear decline of x-ray attenuation could be used to determine the time point of edema onset that requires a period of very severe ischemia.\(^8\) Moreover, the relatively simple CT method allows determination of the extent of edema within an arterial territory at risk. It has been shown that this extent is associated with the risk of secondary hemorrhage after treatment with tissue plasminogen activator (tPA).\(^9\) I do not agree with the authors that any study could prove that the risk of cerebral hemorrhage increases with time after tPA administration. It is more likely that the extent of very severe ischemia determines this risk.\(^10\) The slogan “Time is brain” is useful for discussion with laypersons but misleading. I think it is more correct to say that “perfusion is brain,” and time is an important cofactor. The ticking clock is not needed. It may keep away a promising treatment from patients who really need it.\(^11\) The clinical status of the patient tells us that the brain is at risk, and CT (and probably diffusion-weighted MRI) depicts the volume of tissue that is already damaged. Do we really need more information for the decision to treat a patient with thrombolytics, neuroprotective agents, or decompressive surgery?

Joseph S. Jeret, MD
Rockville Centre, New York

Jonathan Golledge, MChir
Department of Vascular Surgery
Repatriation General Hospital
Daw Park, South Australia

Rüdiger von Kummer, MD
Department of Radiology/Neuroradiology
Technische Universität
Dresden, Germany


Response

I read with interest the comments of Dr Jeret regarding our article published in Stroke this year. Dr Jeret correctly states that a number of the series of carotid angioplasty were small, while in general the carotid endarterectomy series were larger. Dr Jeret also points out correctly that carotid stenting is an evolving technique at present. It is also true to state that carotid endarterectomy has been demonstrated in enormous randomized controlled trials as the treatment of choice for patients with symptomatic severe carotid stenosis; unfortunately, such data is not available for carotid stenting. Dr Jeret states “I view stenting as a safer, less-invasive approach for my patients—provided that they are not part of the physician’s ‘learning curve.’

Jonathan Golledge, MChir
Department of Vascular Surgery
Repatriation General Hospital
Daw Park, South Australia

Letters to the Editor

Response

We appreciate the comments of Dr von Kummer concerning our recent publication.1 His comments concern several issues: (1) the direct application of experimental results to the clinical situation, (2) the problem was misplaced, but this cannot be determined unless this is done, (3) the sodium clock to work, just one region of severe ischemia and/or microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998;65:1-9.


Response

We appreciate the comments of Dr von Kummer concerning our recent publication.1 His comments concern several issues: (1) the direct application of experimental results to the clinical situation, (2) the problem was misplaced, but this cannot be determined unless this is done, (3) the sodium clock to work, just one region of severe ischemia and/or microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998;65:1-9.


Response

We appreciate the comments of Dr von Kummer concerning our recent publication.1 His comments concern several issues: (1) the direct application of experimental results to the clinical situation, (2) the problem was misplaced, but this cannot be determined unless this is done, (3) the sodium clock to work, just one region of severe ischemia and/or microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998;65:1-9.


Response

We appreciate the comments of Dr von Kummer concerning our recent publication.1 His comments concern several issues: (1) the direct application of experimental results to the clinical situation, (2) the problem was misplaced, but this cannot be determined unless this is done, (3) the sodium clock to work, just one region of severe ischemia and/or microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998;65:1-9.


Response

We appreciate the comments of Dr von Kummer concerning our recent publication.1 His comments concern several issues: (1) the direct application of experimental results to the clinical situation, (2) the problem was misplaced, but this cannot be determined unless this is done, (3) the sodium clock to work, just one region of severe ischemia and/or microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998;65:1-9.

esis that there are other more sensitive ways to segregate appropriate patients for thrombolysis. However, as of now, it is still a hypothesis.

Dr von Kummer states that the authors “regard the time of stroke onset” essential before initiating thrombolytic treatment.” Actually, in the United States, this is the standard of care, independent of what the authors, or Dr von Kummer, regard as ideal. The time window of 3 hours has been supported by several recent studies. Indeed, time might not be the perfect arbitrator of the effectiveness of tPA and the occurrence of hemorrhage.

We certainly agree that there may very well be individual differences in the pattern of evolution of the ischemic process that interact with vulnerability to thrombolysis. In fact, in published studies, we discuss the relevant clinical conditions that alter the evolution of ischemia. For the foreseeable future, though, we feel it is a compelling goal to develop methods that extend the opportunity of thrombolysis to as many patients as possible, in particular to those in whom the onset is not known. We feel the methods described here are sufficiently promising that the extensive effort required to test them prospectively in humans is warranted.

The current standard of stroke care in the United States is based on onset time. Although this might be a first faltering step in the evolution of truly rational stroke care, it certainly represents an improvement over the period when time after onset was more or less ignored in stroke therapy. This anti-time argument should really be directed at the design of trials for thrombolytic agents. It is important to think of the future, not the present or past.

Dr von Kummer ascribes to our work that “the risk of cerebral hemorrhage increases with time after tPA administration.” However, we merely cited the results of Clark et al, who clearly document that hemorrhage becomes important in limiting the benefit of intravenous tPA between 3 to 5 hours after onset, whereas before 3 hours, the benefits of tPA outweigh the damage from hemorrhage.

We disagree with the statement that “the ticking clock is not needed. It may keep away a promising treatment from patients who really need it.” If the [Na+] increase is taken from the region of maximal ischemia, this region could be at risk for hemorrhage after thrombolysis and recirculation, in contrast to a more highly perfused region where the blood-brain barrier is intact. Alternatively, if this method of determining onset time were used in all possible candidates for thrombolytic therapy, it is possible that some strokes would be found to have occurred earlier than the patients were aware, that a region with severely ischemic tissue had been there longer than the clinical symptoms indicated.

Fifth, we do think that we need “more information for the decision to treat,” including perhaps the sodium clock. It is hard to imagine not trying to explore new techniques just because the present methods, such as CT or diffusion-weighted MRI (DWI), seem satisfactory. Although the proposed method for [Na+] determination in humans using MRI is currently impractical for wide application to ischemic stroke, so was the use CT in 1975 and DWI in 1989. If a method proves useful, then it will be used, as has happened with CT, MRI, and DWI.

Stephen C. Jones, PhD
Department of Anesthesiology
Allegheny General Hospital
Pittsburgh, Pennsylvania

Thomas A. Kent, MD
Neurology Department
University of Texas Medical Branch
Galveston, Texas

D. Kyle Kim, MD, PhD
Department of Neurological Surgery
Allegheny General Hospital
Pittsburgh, Pennsylvania

Association Between Physiological Homeostasis and Early Recovery After Stroke

To the Editor:

Stroke patients who are managed in an organized (stroke unit) setting are more likely to make a good recovery than those who receive conventional care in general wards, an effect that has been attributed to the coordinated rehabilitation input. However, recent descriptive information from 2 Norwegian trials now indicates that some of the benefits of stroke unit care may also be due to acute medical interventions. In particular, these units employed early mobilization and the routine use of intravenous saline, plus selective use of antipyretic and antibiotic medication, oxygen, and insulin. We therefore wished to test the hypothesis that stroke patients who manage to maintain key physiological variables (osmolarity, temperature, oxygen saturation, blood glucose) within a narrow physiological range are more likely to enjoy an early recovery and better functional outcome.

We carried out a case-control study, recruiting consecutive individuals admitted to a large, urban teaching hospital with a clinical diagnosis of stroke in the previous 24 hours that was confirmed on CT scan. Patients were assessed on admission, day 3, and day 7 after stroke with the Scandinavian Stroke Scale, Barthel Index, and modified Rankin scale. Physiological variables were recorded up to 4 times daily as part of routine clinical care.

We compared the characteristics of patients who showed no major deviation from normal physiological values during the first 3 days (defined as a peak calculated serum osmolarity <300 mOsm/kg, peak temperature ≤37.5°C, peak blood glucose ≤10 mmol/L, minimum oxygen saturation ≥93%) compared with those who showed abnormalities of at least 1 of those variables. We controlled for the key predictors of stroke outcome by using a frequency-matching schedule, matching for age, prestroke disability (Rankin scale score) and initial stroke severity (Scandinavian Stroke Scale score). Matching of cases and controls was conducted blinded to the outcome data.

During a 3-month period, 102 eligible patients were admitted, of whom 35 showed no major physiological homeostatic upset in the first 3 days after stroke; we were able to match 28 of those

<table>
<thead>
<tr>
<th>Physiological Homeostasis and Recovery After Stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A (Normal Physiological Observations)</td>
</tr>
<tr>
<td>Group B (Abnormal Physiological Observations)</td>
</tr>
<tr>
<td>P</td>
</tr>
<tr>
<td>Baseline characteristics</td>
</tr>
<tr>
<td>Number</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Sex (male:female)</td>
</tr>
<tr>
<td>Independent before stroke</td>
</tr>
<tr>
<td>Stroke severity (baseline SSS)</td>
</tr>
<tr>
<td>Living alone</td>
</tr>
<tr>
<td>Stroke subtype</td>
</tr>
<tr>
<td>Total anterior circulation infarct</td>
</tr>
<tr>
<td>Partial anterior circulation infarct</td>
</tr>
<tr>
<td>Lacunar infarct</td>
</tr>
<tr>
<td>Posterior circulation infarct</td>
</tr>
<tr>
<td>Primary intracerebral hemorrhage</td>
</tr>
<tr>
<td>Admission delay (hours from symptom onset to hospital admission)</td>
</tr>
<tr>
<td>Physiological features (days 0–3)</td>
</tr>
<tr>
<td>Peak blood glucose, mmol/L</td>
</tr>
<tr>
<td>Peak serum osmolarity, mOsm/kg</td>
</tr>
<tr>
<td>Peak temperature, °C</td>
</tr>
<tr>
<td>Minimum oxygen saturation (%)</td>
</tr>
<tr>
<td>Outcomes</td>
</tr>
<tr>
<td>SSS score (day 3)</td>
</tr>
<tr>
<td>Change in SSS score (day 3–day 0)</td>
</tr>
<tr>
<td>Neurological improvement (improving &gt;3 points on SSS)</td>
</tr>
<tr>
<td>Barthel Index (day 3)</td>
</tr>
<tr>
<td>Independent (Rankin 0–2) on day 7</td>
</tr>
<tr>
<td>Discharge home after acute care</td>
</tr>
</tbody>
</table>

Data are presented as the median (interquartile range) or the number in each category. Statistical analysis used the Mann-Whitney U test, χ² test, or Mantel-Haenszel odds ratio. SSS indicates Scandinavian Stroke Scale.

*Data used in matching are shown for reference only.
patients (group A) with 28 who showed 1 or more physiological abnormalities (group B). The main results are outlined in the Table. The 2 patient groups were well balanced for age, gender, prestroke independence, initial stroke severity and stroke subtype, and the prevalence of comorbidities. Patients who maintained physiological homeostasis (group A) showed improved outcomes across a range of measures.

These results lend support to the concept that some of the neurological impairment occurring in the acute phase of stroke is reversible and may be exacerbated by physiological abnormalities. In particular, hyperglycemia may be neurotoxic through the promotion of lactic acidosis, dehydration and hypotension may impair cerebral perfusion to ischemic brain tissue, and pyrexia appears to be neurotoxic. The recent descriptions of some stroke unit practices suggest that intervening to maintain key physiological variables within narrow limits (in particular, avoiding extremes of blood glucose concentration, pyrexia, dehydration, and oxygen desaturation) may assist neurological recovery after stroke. We believe that further clinical trials of physiological control in acute stroke are justifiable and could focus on hydration, pyrexia control, blood glucose control, and prevention of hypoxia.

*Funded by Chest, Heart and Stroke, Scotland.*

**P. Langhorne, PhD, FRCP**
**B. Li Pak Tong, BSc**
**D.J. Stott, MD, FRCP**

*Academic Section of Geriatric Medicine*
*Royal Infirmary*
*Glasgow, United Kingdom*


**Response**

It is of great interest for us that Langhorne and coworkers have been able to achieve similar results. We think this is an important area for more research because control of such physiological variables may be the most important neuroprotective options in acute stroke patients. However, in traditional acute care or intensive care, control of physiological variables has very often been associated with intensive monitoring while the patient has been immobilized in bed. It is worth noting that in our trial early mobilization was even more important for a better outcome than control of physiological variables. Hence, control of these physiological variables should probably occur simultaneously with an early mobilization and start of rehabilitation. That advanced monitoring is not necessarily beneficial was shown for cardiological patients several years ago. If prolonged bedrest occurs, the beneficial effect may disappear. In our stroke unit we now perform studies to look at the effects of our very early mobilization on physiological variables. Our hypothesis is that early mobilization may not only reduce bed-associated complications and enhance recovery but may also contribute to more optimal control of some of the physiological variables.

Until more data are accumulated, we will continue the approach to acute stroke care that we developed during our stroke trial. Our approach can be summarized in the following way: Acute stroke patients need acute medical care in order to control physiological variables, and they need acute mobilization/training to reduce complications and enhance recovery. One reason that stroke units which combine acute care and acute rehabilitation are very beneficial might be that such units are able to offer both acute care and acute rehabilitation and that they are able to offer these options simultaneously. We think the results in the letter from Langhorne and coworkers support our approach, but we agree that more research is needed in this important field to achieve more knowledge and to improve acute care of stroke.

**Bent Indredavik, MD, PhD**
**Stroke Unit**
**Department of Medicine**
**University Hospital of Trondheim**
**Trondheim, Norway**

Association Between Physiological Homeostasis and Early Recovery After Stroke
P. Langhorne, B. Li Pak Tong and D.J. Stott

Stroke. 2000;31:2517-2527
doi: 10.1161/01.STR.31.10.2517-f
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/31/10/2517.7

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/